AstraZeneca Pharma India Launches COE For Severe Asthma Treatment In Mumbai

The newly inaugurated CoE is equipped with advanced technologies for asthma management including biologics checklists and data-driven treatment approaches. Further, the center is expected to screen approximately 7,500+ patients within the first 12 months.

AstraZeneca Pharma India Ltd, a biopharmaceutical company, has inaugurated a Centre of Excellence (COE) for severe asthma treatment in Bramha Kumaris Hospital, Mumbai.

The newly inaugurated CoE is equipped with advanced technologies for asthma management including biologics checklists and data-driven treatment approaches. Further, the centre is expected to screen approximately 7,500+ patients within the first 12 months.

This advanced centre will further advocate a systematic and guidelines-based approach to identify and treat severe asthma patients.

On the collaboration, Dr Anil Kukreja, VP Medical Affairs & Regulatory, AstraZeneca India, said, "Through collaborative efforts with local partners, ongoing research, and knowledge-sharing, we aim to improve the lives of severe asthma patients. Our journey continues as we strive to redefine the future of respiratory health."

Additionally, to ensure seamless collaboration with the healthcare ecosystem, AstraZeneca is in discussion with potential local partners to aid establishment of these centres. The initiative seeks to eliminate preventable severe asthma attacks and hospitalisations.

Sharing her views, BK Yoginiben, executive director, Bramha Kumaris Hospital said, "This latest initiative in partnership with AstraZeneca India, reflects our shared commitment to enhancing healthcare outcomes. We look forward to a fruitful collaboration that not only transforms severe asthma treatment but also brings about positive changes in the lives of patients, aligning with our vision for comprehensive and compassionate healthcare.’’

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas including oncology, cardiovascular, renal & metabolism and respiratory.

Established in 1979, in India, the company aims to deliver life-changing medicines to patients through innovative science and global excellence in development.

This initiative by AstraZeneca comes at a time when Asthma has become a rising global concern which affects over 339 million people annually, with more than 15 million cases in India alone. Especially in Mumbai, which has high humid levels leading to frequent triggering of asthma attacks in patients.

In view of this several organisations are coming up with initiatives to address it. In September, Lupin’s digital asthma educator platform ‘JAI’ crossed 10,000 onboarded patients since its launch. JAI claims to offer a solution to bridge this gap by providing personalised, one-on-one training sessions to over 10,000 patients who have joined the platform. These sessions are conducted by qualified asthma educators who focus on teaching correct inhalation techniques.